Evidence map›Paper›PMID 41995582›Full record

ArticleEuropean journal of neurology2026

Erythrocyte Fragility in Progressive Multiple Sclerosis.

Carmen Jacob, Thomas E Williams, Charlotte M Stuart, Aviva Witkover, Simon Hametner, Hans Lassmann, Charles R M Bangham, Jeremy Chataway, Ian Galea

Abstract read
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carmen JacobClinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Thomas E WilliamsQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
Charlotte M StuartClinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Aviva WitkoverDepartment of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
Simon HametnerDivision of Neurochemistry and Neuropathology, Medical University of Vienna, Vienna, Austria.
Hans LassmannDepartment of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-8617-5052
Charles R M BanghamDepartment of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
Jeremy ChatawayQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
Ian GaleaClinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Funding

Multiple Sclerosis Society 68Multiple Sclerosis Society 83Multiple Sclerosis Society 996National Institute for Health and Care Research HTA 15/57/143Rosetrees Trust PGL-pre2019/10013US National Multiple Sclerosis Society RG-1607-24869US National Multiple Sclerosis Society SI-1709-29165
6 · The paper itself

Abstract

backgroundAberrant iron homeostasis is increasingly recognized as a key pathological feature in progressive multiple sclerosis (MS). Although the source of excess brain iron remains unclear, haemoglobin is one possible source. To test this hypothesis, we conducted a case-control study to determine whether erythrocytes are more fragile in people with progressive MS (PwPMS) and examined associations between erythrocyte fragility and brain atrophy.

methodsPwPMS and control individuals were recruited from two centres. Two measures of erythrocyte fragility were assessed at baseline: the Median Corpuscular Fragility (MCF) and haemolysis curve slope. A subset of PwPMS in one centre underwent MR imaging at the same time as osmotic fragility testing and annually for three years thereafter.

resultsA total of 174 participants were included (75 PwPMS, 99 controls), with MRI data available for 44 PwPMS. No significant differences in the MCF were observed between PwPMS and controls in either the full or age-matched cohorts. However, the haemolysis curve slope in PwPMS was less steep than healthy controls (median PwPMS = -24.76, controls = -28.73, p = 0.017), consistent with a subpopulation of fragile erythrocytes, with a similar trend in the age-matched subset (p = 0.056). Erythrocyte fragility was associated with normalized whole brain volume at the time of osmotic fragility testing and up to three years thereafter.

conclusionsExtracellular haemoglobin from lysis of an erythrocyte subpopulation may contribute to neurodegeneration in progressive MS. Further research is warranted to elucidate the interplay between erythrocyte health, inflammation and neurodegeneration, which may open avenues for novel therapeutic strategies.

Indexed as

ErythrocytesMultiple Sclerosis, Chronic ProgressiveOsmotic FragilityAdultAgedAtrophyBrainCase-Control StudiesFemaleHemolysisHumansMagnetic Resonance ImagingMaleMiddle Agederythrocytehaemoglobinhaemolysismultiple sclerosisosmotic fragility

Identifiers

PMID41995582
PMCPMC13088977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.